NCT06067191View on ClinicalTrials.gov

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

PHASE1CompletedINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

DRUG

RV299

Oral Suspension

DRUG

Placebo

matching placebo

Trial Locations (1)

Unknown

Pfizer, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT06067191 - Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV) | Biotech Hunter | Biotech Hunter